EXEL  valuation analysis

Name: Exelixis, Inc
Description: Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. (more)
Industry: Biotechnology
Last 10Q10Qs are quarterly reports which contain a company's financial figures. We use these to calculate the FFER.: May 06, 2021
Market cap: $7.21B (363rd)
Sales(TTM): $1.75B (476th)
Earnings(TTM): $148.16M (432nd)

FFER: 2.49 (why)
Actual price: $22.43
FFEThis is Exelixis, Inc's the estimated price. FFEs are the denominator of the FFER ratio.: $9.06
Quantile: EXEL is very expensive given its fundamentals.
Prices as of EOD 2021-06-16
Price & Estimates
Sales & Earnings history (TTM)
  • Exelixis, Inc's sales grew by 78.5% ($979.24M to $1.75B) over one year against a market average growth of 6.5%.
Earnings / MarketCap
Exelixis, Inc
"Biotechnology" industry
Sales / MarketCap
Exelixis, Inc
"Biotechnology" industry
Book / MarketCap
Exelixis, Inc
"Biotechnology" industry
Equity / Assets
Exelixis, Inc
"Biotechnology" industry